FY2025 EPS Estimate for Stoke Therapeutics Raised by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - HC Wainwright increased their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a report issued on Tuesday, February 18th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($2.68) per share for the year, up from their previous forecast of ($2.82). HC Wainwright has a "Buy" rating and a $47.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics' FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($1.65) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at $0.45 EPS.

Several other brokerages have also recently issued reports on STOK. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. Chardan Capital reiterated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $23.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded down $0.25 during trading on Friday, reaching $8.25. The company had a trading volume of 671,555 shares, compared to its average volume of 879,368. The stock's fifty day moving average price is $10.47 and its 200 day moving average price is $12.22. Stoke Therapeutics has a fifty-two week low of $5.60 and a fifty-two week high of $17.58. The firm has a market capitalization of $436.98 million, a price-to-earnings ratio of -3.93 and a beta of 0.95.

Remove Ads

Institutional Trading of Stoke Therapeutics

Several large investors have recently modified their holdings of STOK. RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after acquiring an additional 265,395 shares in the last quarter. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics during the fourth quarter valued at $35,001,000. State Street Corp increased its position in Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after purchasing an additional 137,145 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company's stock valued at $14,901,000 after purchasing an additional 38,446 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the transaction, the chief executive officer now directly owns 68,671 shares of the company's stock, valued at $877,615.38. This trade represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.